Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics, Inc. (TNYA)
:TNYA
TNYA Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TNYA Stock 12 Month Forecast
Average Price Target
$11.20
▲(1523.19% Upside)
| Highest Price Target$40.00 | Average Price Target$11.20 | Lowest Price Target$3.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$3
Buy
334.78%
Upside
Reiterated
07/31/25
William Blair
―
Buy
―
Reiterated
07/30/25
H.C. Wainwright
$5
Buy
624.64%
Upside
Reiterated
07/30/25
Positive Safety Reviews and Promising Interim Data Bolster Buy Rating for Tenaya TherapeuticsValuation and Risks. We maintain our Buy rating and $5 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile. Pipeline assets' contribution to our valuation are as follows: (1) TN-201 at 28%; (2) TN-301 at 49%; and (3) TN-401 at 23%. Factors that could impede reaching our price target include failed or inconclusive clinical trials, the inability of the company to secure adequate funding to progress its drugs through the development pathway or the occurrence of dilutive capital raises.
Morgan Stanley
$5
Buy
624.64%
Upside
Reiterated
05/09/25
TD Cowen
―
Buy
―
Reiterated
05/08/25
Piper Sandler
$40
Buy
5697.10%
Upside
Reiterated
05/08/25
Leerink Partners
$3
Buy
334.78%
Upside
Reiterated
05/07/25
Canaccord Genuity
$6
Buy
769.57%
Upside
Reiterated
03/24/25
Chardan Capital
$18→$9
Buy
1204.35%
Upside
Reiterated
03/11/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$3
Buy
334.78%
Upside
Reiterated
07/31/25
William Blair
―
Buy
―
Reiterated
07/30/25
H.C. Wainwright
$5
Buy
624.64%
Upside
Reiterated
07/30/25
Positive Safety Reviews and Promising Interim Data Bolster Buy Rating for Tenaya TherapeuticsValuation and Risks. We maintain our Buy rating and $5 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile. Pipeline assets' contribution to our valuation are as follows: (1) TN-201 at 28%; (2) TN-301 at 49%; and (3) TN-401 at 23%. Factors that could impede reaching our price target include failed or inconclusive clinical trials, the inability of the company to secure adequate funding to progress its drugs through the development pathway or the occurrence of dilutive capital raises.
Morgan Stanley
$5
Buy
624.64%
Upside
Reiterated
05/09/25
TD Cowen
―
Buy
―
Reiterated
05/08/25
Piper Sandler
$40
Buy
5697.10%
Upside
Reiterated
05/08/25
Leerink Partners
$3
Buy
334.78%
Upside
Reiterated
05/07/25
Canaccord Genuity
$6
Buy
769.57%
Upside
Reiterated
03/24/25
Chardan Capital
$18→$9
Buy
1204.35%
Upside
Reiterated
03/11/25
Best Analysts Covering Tenaya Therapeutics
1 Month
xxx
Success Rate
5/12 ratings generated profit
Average Return
-4.31%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 41.67% of your transactions generating a profit, with an average return of -4.31% per trade.
3 Months
xxx
Success Rate
7/13 ratings generated profit
Average Return
+8.32%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +8.32% per trade.
1 Year
Success Rate
5/13 ratings generated profit
Average Return
-25.03%
reiterated a buy rating 7 days ago
Copying Cory Jubinville, PhD's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -25.03% per trade.
2 Years
xxx
Success Rate
4/13 ratings generated profit
Average Return
-39.15%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of -39.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TNYA Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jul 25
Strong Buy
8
15
17
21
11
Buy
4
6
3
5
3
Hold
0
1
1
1
0
Sell
3
2
2
2
1
Strong Sell
0
0
0
0
0
total
15
24
23
29
15
Each month's total comprises the sum of three months' worth of ratings.
TNYA Financial Forecast
TNYA Stock Forecast FAQ
What is TNYA’s average 12-month price target, according to analysts?
Based on analyst ratings, Tenaya Therapeutics, Inc.’s 12-month average price target is 11.20.
What is TNYA’s upside potential, based on the analysts’ average price target?
Tenaya Therapeutics, Inc. has 1523.19% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TNYA a Buy, Sell or Hold?
Tenaya Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Tenaya Therapeutics, Inc.’s price target?
The average price target for Tenaya Therapeutics, Inc. is 11.20. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $3.00. The average price target represents 1523.19% Increase from the current price of $0.69.
The highest analyst price target is $40.00 ,the lowest forecast is $3.00. The average price target represents 1523.19% Increase from the current price of $0.69.
What do analysts say about Tenaya Therapeutics, Inc.?
Tenaya Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of TNYA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.